Positive Vote for Arimoclomol in Treating Rare Genetic Disorder Niemann-Pick Disease Type C
In a recent vote, the Food and Drug Administration's Genetic Metabolic Diseases Advisory Committee voted 11-5 in favor of...
Niemann-Pick disease type C
Zevra Therapeutics Shares Fall as FDA Extends Arimoclomol Review
**Lead:** Zevra Therapeutics faces a setback as FDA delays review of its lead drug, causing shares to plummet by...
FDA Extends Review of Zevra’s Arimoclomol for Niemann-Pick Disease
In a race against time, the U.S. Food and Drug Administration has extended its review of Zevra Therapeutics' application...
Xoma to Make $1M Milestone Payment to LadRx After FDA Accepts Zevra Application for Arimoclomol
Xoma will make a $1 million milestone payment to LadRx after the FDA accepted Zevra Therapeutics' new drug application...
Zevra Therapeutics Resubmits Arimoclomol Application for FDA Approval
Zevra Therapeutics has resubmitted a new drug application to the FDA for its lead product candidate arimoclomol, which treats...